11 results about "Vein injection" patented technology

The invention belongs to the field of biological medicines, and particularly discloses application of extracellular vesicles EVs carrying CD35 functional molecules in preparation of medicines for treating sepsis-related multi-organ injury, preferably, the EVs are derived from human podocytes or other cells or tool cells capable of naturally or engineered expressing CD35, and the EVs are administrated through caudal vein injection and can be used for preparing medicines for treating sepsis-related multi-organ injury. Normal saline is taken as a carrier, and the dosage of 1 * 10 < 10 > EVs each time is once every 12 hours and twice continuously. It is proved for the first time that EVs carries CD35 to inhibit circulation mononuclear cell complement activation (the EVs are combined with C3b to block downstream complement cascade reaction), migration of mononuclear cells to the kidney, the heart, the liver and the lung is reduced, and therefore multi-organ inflammation damage and cell apoptosis are relieved. In a cecum ligation perforation (CLP) sepsis model, it is proved that the medicine significantly improves the survival rate of mice, improves renal functions (reduces creatinine / urea nitrogen) and kidney pathological tissue damage, and meanwhile relieves pathological damage of multiple organs of the heart, the liver and the lung. The invention provides a new treatment strategy and drug candidate for sepsis-related multi-organ dysfunction.

The invention provides an application of an E3 ubiquitin ligase RLIM gene inhibitor in preparation of a medicine for treating ovarian aging or injury. Experiments find that the expression level of the RLIM gene in the ovary is positively correlated with the aging degree, and the expression of the RLIM gene is remarkably improved along with age increase. In-vivo and in-vitro experiments show that ovarian granular cell senescence can be effectively delayed and ovarian functions can be improved by inhibiting RLIM expression, and particularly, the proportion of atresia follicles is reduced, the number of healthy follicles is increased, and serum AMH and E2 levels are remarkably improved. The pharmaceutical composition provided by the invention comprises a siRNA inhibitor (preferably, siRLIM-2) of specific targeting RLIM and a nano-liposome carrier, and efficient targeting delivery can be realized through tail vein injection. The treatment scheme has no toxic effect on important organs, is high in safety, and provides a new effective means for treatment of ovarian aging and related diseases.

The invention belongs to the technical field of medicines, and particularly relates to application of CD47 as a target spot in treatment of heat stroke. The invention provides application of CD47 in preparation of a medicine or a medicine composition for treating heat stroke. The CD47 is used as a heat stroke treatment target for the first time, and a remarkable treatment effect is achieved. In a heat stroke mouse model, the function damage of multiple organs such as lung, kidney and the like caused by heat stroke can be relieved by injecting the CD47 monoclonal antibody into the caudal vein, the survival rate of the heat stroke mouse is increased, and the survival rate can be increased to about 80% by applying the CD47 monoclonal antibody under the dosage of 10 mg / kg. Therefore, the CD47 can be used as a therapeutic target for preparing the medicine for treating the heat stroke.

The invention discloses shRNA (short hairpin ribonucleic acid) capable of specifically inhibiting circTNK2-Mus expression and application of the shRNA. The nucleotide sequence of the shRNA is shown as SEQ ID NO. 5. The invention also provides an oligonucleotide sequence (as shown in SEQ ID NO.3-4) for coding the shRNA, a recombinant LV3 lentivirus plasmid containing the sequence, a recombinant lentivirus packaged by the recombinant LV3 lentivirus plasmid, a pharmaceutical composition containing the virus and application of the recombinant lentivirus. Experiments prove that in a cholestasis-induced hepatic fibrosis animal model, the expression of circTNK2-Mus in liver tissues can be efficiently and specifically knocked down by performing caudal vein injection on the recombinant lentivirus, the pathological indexes of fibrosis are remarkably improved, and the occurrence and development of hepatic fibrosis are effectively prevented. The invention provides a brand-new circRNA target spot and a gene therapy candidate drug with great potential for hepatic fibrosis.

The invention discloses a volume quantitative control method of a retina intravenous injection system, which belongs to the technical field of ophthalmology robots, and comprises the following steps: firstly, designing a smooth injection volume curve as an expected volume of the quantitative control method; aiming at disturbance characteristics of different stages of the injection system, an evolution observer is designed to estimate unknown disturbance and compensate the unknown disturbance into a controller; an equivalent control law designed by adopting an integral sliding mode surface and an evolution observer is combined with a switching control law designed by adopting a self-adaptive gain, and an obtained total control law can realize reliable tracking of an expected volume. The method can ensure high-precision closed-loop control of the drug volume in the retinal intravenous injection operation, and has robust tracking performance.

This invention discloses a highly efficient heart-specific promoter, a recombinant vector containing this promoter, and their applications. The highly efficient heart-specific promoter cTnTplus provided by this invention contains the core sequence of the chicken-derived cardiac troponin T promoter and the mouse troponin 2 gene cis-regulatory motif CS-CRM4 tandemly upstream of it. This motif functions as an enhancer element. In vitro infection of rat H9C2 cardiomyocytes showed that the eGFP fluorescence intensity driven by the cTnTplus promoter was significantly higher than that of the original cTnT promoter. In vivo, after tail vein injection of AAV virus, the eGFP expression of the cTnTplus promoter in mouse hearts was significantly increased compared to the cTnT promoter, and no obvious fluorescence was observed in liver tissue, indicating a significant reduction in liver leakage. The promoter provided by this invention possesses both high transcriptional activity and myocardial specificity, providing a safe and efficient tool for cardiac gene therapy.

The utility model relates to medical technology field, concretely is a new born baby umbilical artery and vein catheterization restraint strap, including sticky tape, set up the round opening on sticky tape, the elastic restraint sleeve of one end sealed connection round opening, set up the seal clamp of elastic restraint sleeve end part, the seal clamp is used to clamp the end part of elastic restraint sleeve and seal, when needing to inject medicine, through seal clamp can open elastic restraint sleeve, stretch out inside umbilical artery and vein catheterization and carry out umbilical artery and vein injection, after injection, disinfect injection point, through seal clamp can be sealed again elastic restraint sleeve, prevent outside bacterial infection, the utility model can be to the new born baby umbilical artery and vein catheterization restraint and seal, avoid umbilical artery and vein to contaminate outside bacteria, also convenient for injection administration, can continue to use after injection administration, and the practicality is better.

The invention provides a construction method of a retinal vein occlusion animal model, and belongs to the technical field of medicines. The method comprises the following steps of: performing eyeball surface anesthesia on an anesthetized non-human primate animal, puncturing an eyeball after disinfection to establish two sclera tunnels, respectively inserting an illumination optical fiber and an intraocular laser optical fiber into the two sclera tunnels, then injecting a photosensitizer through limb vein, immediately performing laser photocoagulation on the retinal vein under illumination of the illumination optical fiber after injection, and performing laser photocoagulation on the retinal vein under the illumination of the illumination optical fiber. And obtaining the retinal vein occlusion animal model. According to the method, the retinal vein occlusion model can be successfully constructed, secondary macular edema and vascular recanalization are carried out for a long time and can be maintained for 4-5 weeks, the manifestation sign of retinal hemorrhage after retinal vein occlusion is close to that of human beings, and the method has clinical drug responsiveness, shows the clinical research value and has good application prospects. And a good research model is provided for research in the aspects of etiology, pathology and therapeutics.

The application belongs to the technical field of ophthalmic robots, and provides a gas buffer injection system for retinal vein injection surgery, which comprises a flowmeter, a tee A, a gas pressure sensor, a sample injector and a micro linear servo driver, three interfaces of the tee A are connected with the flowmeter, the gas pressure sensor and the sample injector respectively, the sample injector is connected with the micro linear servo driver, the rear end of the micro linear servo driver is provided with a pressure sensor, the pressure sensor is used for measuring the pressure of the top gas in the tee A, and the gas is below a viscous liquid. A gas buffer injection method is also provided, according to the optimal injection volume curve and the feedback data of the gas pressure sensor, the movement distance of the push rod of the micro linear servo driver is adjusted in real time, and injection is carried out according to the optimal injection volume curve. The application adds gas in the pipeline, uses the gas to buffer the injection pressure, takes the gas pressure as the feedback data, adjusts the injection speed, and realizes smooth drug injection.

The invention discloses a method for preparing an anti-osteoporosis medicine for inhibiting bone resorption by adjusting NFIA for the first time. The invention finds that NFIA inhibits osteoclast differentiation and bone resorption activity by inhibiting transcription of RANKL. The cancellous bone mass of the mouse of which the NFIA gene is specifically knocked out in osteogenic precursor cells and mesenchymal cells is reduced; the ovariectomized mouse bone loss induced by ovariectomized mouse bone loss can be relieved by performing caudal vein injection on the adeno-associated virus overexpressing the The medicine prepared according to the invention has the effect of preventing and treating osteoporosis by enhancing NFIA expression or enhancing the protein function of NFIA, inhibiting osteoclast differentiation, reducing bone resorption and increasing body bone mass.

The application discloses a kind of methods for constructing deep vein thrombosis mouse model by regulating Pyk2 gene expression.The method comprises the following steps: constructing knockdown or overexpression vector for Pyk2 gene; by tail vein injection, the vector is introduced into mouse in vivo, the in vivo transient regulation of Pyk2 gene is realized; the inferior vena stenosis method is used to induce deep vein thrombosis; the thrombus macroscopic morphology, wet weight, length and histopathology are detected.The application overcomes the limitation of existing gene knockout model, such as congenital, irreversible and systemic deletion, realizes the targeted, temporary and bidirectional flexible regulation of Pyk2 gene in vascular tissue, and the model has high stability and good repeatability.The model can simulate the pathological state under the same expression level of Pyk2, and is suitable for the screening, evaluation and deep vein thrombosis pathogenesis research of antithrombotic drugs.